Interim report July–September 2020
Third quarter
- Revenue amounted to €262.5m (€212.1m), an increase of 23.8% with an organic growth of 12.3%.
- Operating profit (EBIT) was €27.3m (€14.3m), representing an operating margin of 10.4% (6.7%).
- Net profit amounted to €19.5m (€6.3m), which represents a net profit margin of 7.5% (3.0%).
- EBITDA was €50.1m (€32.5m), an increase of 54.4%. EBITDA margin was 19.1% (15.3%).
- EBITDAaL amounted to €38.1m (€22.3m), corresponding to an EBITDAaL margin of 14.5% (10.5%).
- Net cash flow from operating activities was €41.7m (€22.6m).
- Basic/diluted earnings per share were €0.108 (€0.043).
- Covid-19 had a positive impact on operating performance.
Nine months
- Revenue amounted to €700.1m (€614.7m), an increase of 13.9% with an organic growth of 4.7%.
- Operating profit (EBIT) was €31.4m (€35.7m), a decrease by 11.9%, representing an operating margin of 4.5% (5.8%).
- Net profit amounted to €8.5m (€18.1m), which represents a net profit margin of 1.2% (2.9%).
- EBITDA was €104.4m (€87.3m), an increase of 19.6%. EBITDA margin was 14.9% (14.2%).
- EBITDAaL amounted to €67.3m (€58.3m), an increase by 15.5% corresponding to an EBITDAaL margin of 9.6% (9.5%).
- Net cash flow from operating activities was €116.5m (€62.4m).
- Basic/diluted earnings per share were €0.054 (€0.120).
- Covid-19 had a cumulative negative impact on operating performance.
- Directed share issue of 15 million shares completed in June 2020, net proceeds of €141.9m.
REVENUE AND EARNINGS
|
€ millions (€m) |
Q3 2020 | Q3 2019 | Variance | 9M 2020 | 9M 2019 | Variance | FY 2019 |
| Revenue | 262.5 | 212.1 | 24% | 700.1 | 614.7 | 14% | 844.4 |
| Operating profit (EBIT) | 27.3 | 14.3 | 91% | 31.4 | 35.7 | -12% | 46.5 |
| Operating profit margin | 10.4% | 6.7% | 4.5% | 5.8% | 5.5% | ||
| Net profit | 19.5 | 6.3 | 207% | 8.5 | 18.1 | -53% | 24.7 |
| Net profit margin | 7.5% | 3.0% | 1.2% | 2.9% | 2.9% | ||
| Basic/diluted earnings per share, € | 0.108 | 0.043 | 151% | 0.054 | 0.120 | -55% | 0.168 |
| EBITDA | 50.1 | 32.5 | 54% | 104.4 | 87.3 | 20% | 120.7 |
| EBITDA margin | 19.1% | 15.3% | 14.9% | 14.2% | 14.3% | ||
| EBITDAaL | 38.1 | 22.3 | 71% | 67.3 | 58.3 | 16% | 80.6 |
| EBITDAaL margin | 14.5% | 10.5% | 9.6% | 9.5% | 9.5% | ||
| EBITA | 30.1 | 15.7 | 93% | 44.2 | 39.8 | 11% | 53.7 |
| EBITA margin | 11.5% | 7.4% | 6.3% | 6.5% | 6.4% |
Definition and reconciliation of alternative performance measures are available at www.medicover.com/financial-information.
This is information that Medicover AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication through the agency of the contact person set out below at 7.45 (CET) on 6 November 2020. This interim report and other information about Medicover is available at medicover.com.
For further information, please contact:
Hanna Bjellquist, Head of Investor Relations Phone: +46-70-303-3272
hanna.bjellquist@medicover.com
Medicover is a leading international healthcare and diagnostic services company and was founded in 1995. Medicover operates a large number of ambulatory clinics, hospitals, specialty-care facilities,laboratories and blood-drawing points and the largest markets are Poland and Germany. In 2019, Medicover had revenue around €844 million and 28,800 employees. For more information, go to www.medicover.com